BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 22339910)

  • 1. [Prognostic significance of flow cytometric minimal residual disease in acute myeloid leukemia during aplasia].
    Peng N; Wei H; Lin D; Zhou CL; Liu BC; Wang Y; Liu KQ; Gong BF; Wei SN; Zhang GJ; Liu YT; Gong XY; Qiu SW; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):767-771. PubMed ID: 29081193
    [No Abstract]   [Full Text] [Related]  

  • 2. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
    Ganzel C; Sun Z; Baslan T; Zhang Y; Gönen M; Abdel-Wahab OI; Racevskis J; Garrett-Bakelman F; Lowe SW; Fernandez HF; Ketterling R; Luger SM; Litzow M; Lazarus HM; Rowe JM; Tallman MS; Levine RL; Paietta E
    Leuk Res; 2022 Dec; 123():106971. PubMed ID: 36332294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of flow cytometry in detection of minimal residual disease in cerebrospinal fluid.
    Luo Y; Lin T; Xian L; Zhao Y; Li W; Liu J; Lan M; Shan H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1838-1843. PubMed ID: 38448377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
    Zaliova M; Zuna J; Winkowska L; Janotova I; Skorepova J; Lukes J; Meyer C; Marschalek R; Novak Z; Domansky J; Stary J; Sramkova L; Trka J
    Leukemia; 2024 Jan; 38(1):21-30. PubMed ID: 38001170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
    Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Flow cytometric monitoring of minimal residual diseases in patients with acute leukemia after allogeneic hemapoietic stem cell transplantation].
    Gao YQ; Wu T; Wang H; Tong CR; Zhang WJ; Wang JB; Lu Y; Zhao YL; Zhou JR; Sun Y; Zhang YC; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):84-7. PubMed ID: 22730653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases].
    Tong CR; Wang H; Yang JF; Lin YH; Zhang X; Zhao J; Fei XH; Gu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):748-51. PubMed ID: 22339910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of minimal residual disease in acute myeloid leukemia.
    Kern W; Haferlach C; Haferlach T; Schnittger S
    Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.